AI illustration · not actual product photoDetails from the source.
This catalogue entry records VIP, 10 mg × 10 vials (SKU VP10), using the supplied source listing. The cited dossier describes: Research examines VIP signaling in digestion and secretion, vascular tone, pulmonary circulation, and immune/inflammatory biology. Selected human work studied short-term inhaled aviptadil in pulmonary hypertension and intravenous aviptadil for acute respiratory failure/COVID-19. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- VP10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
Peptide: yes. Vasoactive intestinal peptide is a 28-amino-acid endogenous peptide hormone/neuropeptide. Catalogue entry retained exactly: “VIP” (VP10), “*10vials”; listed price 157 per 10 vials, currency not stated. The abbreviated label does not verify the vial's sequence, terminal modifications, salt, or formulation. [1] [4]
Biological mechanism
VIP acts mainly at VPAC1 and VPAC2, class B G-protein-coupled receptors. In many tissues, receptor activation signals through Gs, adenylyl cyclase and cAMP; downstream effects vary by cell type and include vascular relaxation and gastrointestinal electrolyte/fluid secretion. Some vascular effects involve endothelial nitric-oxide signaling. These pathways are substantially informed by laboratory and animal studies; they do not establish a therapeutic effect for VP10. [4]
Research focus
Research examines VIP signaling in digestion and secretion, vascular tone, pulmonary circulation, and immune/inflammatory biology. Selected human work studied short-term inhaled aviptadil in pulmonary hypertension and intravenous aviptadil for acute respiratory failure/COVID-19. Separate laboratory and animal lung-injury findings remain preclinical. These aviptadil studies do not confirm VP10's composition or status. [3] [4] [5] [6]
Potential applications in the evidence
Pulmonary vascular effects, pulmonary hypertension, acute lung injury/ARDS and severe COVID-19 have been investigated; digestive and immune signaling are also research topics. These are areas of investigation, not established applications or efficacy claims for the catalogue item. Preclinical findings should not be presented as human benefit. [3] [4] [5] [6]
Human evidence
In a small open-label study, 20 people with pulmonary hypertension received a single inhaled aviptadil exposure; researchers reported modest, temporary selective pulmonary vasodilation. It does not establish lasting benefit. [5] In a multicentre placebo-controlled COVID-19 trial of 196 people, the prespecified primary endpoint at day 60 did not reach statistical significance. A secondary survival result was statistically significant, but it does not establish efficacy for VIP generally or VP10; study limitations and subgroup findings warrant caution. [3] [6]
Known and potential effects
VIP's vascular actions can lower blood pressure; gastrointestinal secretion effects can include diarrhea, and flushing is described. In the COVID-19 aviptadil trial, diarrhea occurred more often with aviptadil than placebo (32.8% vs 1.5%). Hypotension occurred in 26.0% vs 21.5%, without a statistically significant difference. The authors reported no unanticipated drug-related serious adverse events in that trial. These findings are specific to that study product, population and setting and do not establish VP10's safety. [4] [6]
Safety and contraindications
Potential blood-pressure lowering and gastrointestinal effects are relevant safety concerns. Safety, interactions and contraindications specific to VP10 cannot be verified because the catalogue does not provide its identity, formulation, quality, sterility or lot documentation. No product-specific contraindication profile or safety guarantee can be inferred from studies of other preparations. [4] [6]
U.S. FDA / regulatory status
FDA records list aviptadil orphan-drug designations for pulmonary arterial hypertension and sarcoidosis; the FDA pulmonary arterial hypertension record explicitly states “Not FDA Approved for Orphan Indication.” I could not verify an FDA-approved VIP/aviptadil product label in the official sources reviewed. Orphan designation is not approval. The manufacturer, lot, formulation source, jurisdiction and approval status of this exact VP10 vial cannot be verified, and status from a different aviptadil preparation must not be transferred to it. [1] [2]
Evidence limitations
Human evidence is limited and specific to studied aviptadil preparations, routes, populations and settings. A small acute physiological study and a randomized trial that did not meet its primary endpoint do not establish durable benefit or long-term safety. Preclinical findings must be kept separate from human evidence. The source label does not establish exact vial identity; there is no owner-supplied evidence to classify VP10 as approved, investigational, compounded or research-only. [3] [4] [5] [6]
Supporting sources
- FDA Substance Record for Aviptadil U.S. Food and Drug Administration · FDA substance database record. Supports: Aviptadil-specific sequence and FDA-recorded orphan designations; does not establish the identity of VP10.
- FDA Orphan Drug Designation: Aviptadil for Pulmonary Arterial Hypertension U.S. Food and Drug Administration · FDA orphan drug database record. Supports: Pulmonary arterial hypertension designation and the explicit status “Not FDA Approved for Orphan Indication.”
- Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure ClinicalTrials.gov, U.S. National Library of Medicine · Clinical trial registry. Supports: Registered human study context, sponsor, design, completion status and trial-reported information.
- Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system F1000Research / PubMed Central · Peer-reviewed review. Supports: VIP identity as a 28-residue peptide, VPAC receptor biology, signaling and physiological/preclinical effects.
- Inhalation of vasoactive intestinal peptide in pulmonary hypertension European Respiratory Society, European Respiratory Journal · Original human clinical study. Supports: Small, acute human pulmonary hypertension study of inhaled aviptadil and reported outcomes.
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial Critical Care Medicine / PubMed, U.S. National Library of Medicine · Randomized controlled trial publication. Supports: Human COVID-19 trial outcomes, primary-endpoint result and adverse-event findings.